# ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection

> **NCT07573943** · PHASE4 · RECRUITING · sponsor: **The Second Affiliated Hospital of Chongqing Medical University** · enrollment: 150 (estimated)

## Conditions studied

- Chronic Hepatitis b

## Interventions

- **DRUG:** Anti-PD-L1 antibody (ASC22)
- **DRUG:** Nucleotide analogs
- **DRUG:** Peg-IFNα

## Key facts

- **NCT ID:** NCT07573943
- **Lead sponsor:** The Second Affiliated Hospital of Chongqing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-21
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-05-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07573943

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07573943, "ASC22 Combined With Peg-IFNa in Achieving Functional Cure in Patients With Chronic Hepatitis B Virus Infection". Retrieved via AI Analytics 2026-09-01 from https://api.ai-analytics.org/clinical/NCT07573943. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*